Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;16(1):6-15.

Promising effect of infliximab on the extent of involvement in ulcerative colitis

Peyman Adibi  1 , Pejman Mollakhalili, Zahra Fallah, Nasser Ebrahimi Daryani, Hossein Ajdarkosh, Hossein Khedmat, Faramarz Derakhshan, Ashraf Karbassi, Mahshid Ashkzari, Hamid Tavakkoli
Affiliations

Promising effect of infliximab on the extent of involvement in ulcerative colitis

Peyman Adibi et al. J Res Med Sci. 2011 Jan.

Abstract

Background: Ulcerative colitis (UC) is a disabling disease with increasing incidence in Iran. In spite of combined medical therapy, some patients eventually undergo total colectomy. Infliximab has proved itself as a rescue therapy and even as an early aggressive therapy for severe extensive UC. Meantime, there are concerns about its complications. The aim of this study was to evaluate the efficacy of infliximab in Iranian refractory UC patients.

Methods: This multi centric case-series study included 29 UC patients receiving two to three of the drugs prednisolone, AZT/6MP and 5ASA but yet having flare-ups. At first, the extent of colon involvement was determined by colonoscopy; then the drug was administered at baseline, 2nd week and 6th week and colonoscopy repeated afterwards. Clinical and laboratory data were also recorded.

Results: In first endoscopy 18 patients (62%) out of 29 suffered from pancolitis and none had normal results. In second examination (done on 19 patients), one was normal and only 8 of 18 (27.6%) had pancolitis. Considering missing cases, at least in 33.3% of patients the drug has reduced the extreme extent of colon involvement. Also a wilcoxon signed ranks test revealed significant reduction of the disease extension after this treatment (p = 0.008). There were only one leucopenic and one hypotensive reactions in short term. The drug showed effectiveness in the term of disease modifying, too.

Conclusions: These data show the usefulness of the drug in refractory UC. Longer follow ups and controlled trials are needed.

Keywords: Colitis; Colon; Infliximab; Ulcerative.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Frequency of colonoscopy findings in all patients
Figure 2
Figure 2
Frequency of colonoscopy findings in patients with second endoscopy done
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Grover P, Kamat D. Management of inflammatory bowel disease. Clin Pediatr. 2007;46(4):359–64. - PubMed
    1. Karlinger K, Györke T, Makö E, Mester A, Tarján Z. The epidemiology and the pathogenesis of inflammatory bo-wel disease. Eur J Radiol. 2000;35(3):154–67. - PubMed
    1. Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. A Review of infliximab use in ulcerative colitis. Clin Ther. 2008;30(2):223–30. - PubMed
    1. Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am. 2006;35(4):821–36. - PubMed
    1. Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD. Ulcerative colitis: diagnosis and treatment. Am Fam Physician. 2007;76(9):1323–30. - PubMed

LinkOut - more resources